These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 33598436)

  • 1. COVID-19, the Future Vaccine and What It Means for Cancer Patients on Immunotherapy.
    El-Shakankery KH; Kefas J; Miller R
    Front Oncol; 2020; 10():631611. PubMed ID: 33598436
    [No Abstract]   [Full Text] [Related]  

  • 2. Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis.
    Saadeldin MK; Abdel-Aziz AK; Abdellatif A
    Med Hypotheses; 2021 Jan; 146():110365. PubMed ID: 33221134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy.
    Koti M; Morales A; Graham CH; Siemens DR
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy.
    Ishikawa E; Yamamoto T; Matsumura A
    Neurol Med Chir (Tokyo); 2017 Jul; 57(7):321-330. PubMed ID: 28539528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
    Vivarelli S; Falzone L; Grillo CM; Scandurra G; Torino F; Libra M
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32785162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Nasopharyngeal Carcinoma Patient With COVID-19 Infection After Immunotherapy: A Case Report and Literature Review.
    Zhai M; Zhang S
    In Vivo; 2020; 34(6):3753-3756. PubMed ID: 33144494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy.
    Bersanelli M; Zielli T; Perrone F; Casartelli C; Pratticò F; Rapacchi E; Camisa R; Tognetto M; Clemente A; Giannarelli D; Rebuzzi SE; Leonetti A; Bordi P; Tiseo M; Buti S
    Immunotherapy; 2020 Oct; 12(15):1139-1148. PubMed ID: 32933369
    [No Abstract]   [Full Text] [Related]  

  • 8. State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough.
    Bersanelli M; Buti S; De Giorgi U; Di Maio M; Giannarelli D; Pignata S; Banna GL
    Crit Rev Oncol Hematol; 2019 Jul; 139():87-90. PubMed ID: 31112887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19.
    Gatto L; Franceschi E; Nunno VD; Brandes AA
    Immunotherapy; 2020 Oct; 12(15):1111-1114. PubMed ID: 32594820
    [No Abstract]   [Full Text] [Related]  

  • 10. Current status of cancer immunotherapy for gynecologic malignancies.
    Nishio H; Iwata T; Aoki D
    Jpn J Clin Oncol; 2021 Feb; 51(2):167-172. PubMed ID: 33244581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.
    Bersanelli M
    Immunotherapy; 2020 Apr; 12(5):269-273. PubMed ID: 32212881
    [No Abstract]   [Full Text] [Related]  

  • 12. Influenza Vaccination Quality Improvement as a Model for COVID-19 Prophylaxis.
    Chin J; Zhou Y; Chen CL; Lomiguen CM; McClelland S; Lee-Wong M
    Cureus; 2021 Jan; 13(1):e12549. PubMed ID: 33437559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic.
    Indini A; Rijavec E; Ghidini M; Cattaneo M; Grossi F
    Eur J Cancer; 2020 Aug; 135():47-50. PubMed ID: 32534244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors.
    Wu Q; Chu Q; Zhang H; Yang B; He X; Zhong Y; Yuan X; Chua MLK; Xie C
    Cancer Commun (Lond); 2020 Aug; 40(8):374-379. PubMed ID: 32666636
    [No Abstract]   [Full Text] [Related]  

  • 15. Humanized Mice as an Effective Evaluation System for Peptide Vaccines and Immune Checkpoint Inhibitors.
    Kametani Y; Ohno Y; Ohshima S; Tsuda B; Yasuda A; Seki T; Ito R; Tokuda Y
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31888191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment.
    Rossi E; Schinzari G; Tortora G
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32699182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19: the use of immunotherapy in metastatic lung cancer.
    Davis AP; Boyer M; Lee JH; Kao SC
    Immunotherapy; 2020 Jun; 12(8):545-548. PubMed ID: 32349579
    [No Abstract]   [Full Text] [Related]  

  • 18. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
    Anagnostou VK; Brahmer JR
    Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic Cancer Vaccine and Immune Checkpoint Inhibitor].
    Mimura K; Kono K
    Gan To Kagaku Ryoho; 2017 Sep; 44(9):733-736. PubMed ID: 28912398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors.
    Gwynn ME; DeRemer DL; Saunders KM; Parikh J; Bollag RJ; Clemmons AB
    J Oncol Pharm Pract; 2020 Apr; 26(3):647-654. PubMed ID: 31474214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.